ARTICLE | Emerging Company Profile
Aurion attracts new investors for corneal cell therapy
Seattle company, with roots in Japan, raises $120M to fund U.S., EU development of therapy to restore vision in patients with corneal endothelial disorders
April 13, 2022 1:53 PM UTC
With its lead program already nearing regulatory submission in Japan, Aurion has attracted a syndicate of institutional investors to push the ophthalmic cell therapy through U.S. and EU development to restore vision in patients with corneal endothelial disorders.
Last year, Aurion Biotech was spun out of one of the world’s largest corneal tissue providers for transplant procedures, CorneaGen Inc., to further develop cell therapy AURN001...